<DOC>
	<DOCNO>NCT01902511</DOCNO>
	<brief_summary>This randomize double blind study conduct patient admit Department Hepatology June 2013 may 2014 ILBS , New Delhi . Patients exclusion criterion undergo bone marrow examination liver biopsy baseline . 60 patient decompensated cirrhosis randomise two limbs- limb A ( 30 patient ) receive G-CSF erythropoietin limb B ( 30 patient ) receive G-CSF alone . The drug give 2 month patient follow 1 year . G-CSF give dose 5 Âµg/kg s/c day 1 , 2 , 3 , 4 , 5 every 3rd day till day 60 ( total 22 dos ) . Erythropoietin give s/c dose 500 IU/Kg twice week 2 month . Follow do day 0,3,7,14,28 , day 42 ( 6 week ) , day 60 ( 2 month ) , day 90 ( 3 month ) , day 180 ( 6 month ) , day 270 ( 9 month ) ; day 360 ( 1 year ) .</brief_summary>
	<brief_title>A Trial Study Influence Growth Factors Bone Marrow Hepatic Regeneration Patients With Decompensated Cirrhosis .</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Subjects age 1865 year All patient know cirrhosis liver portal hypertension compensate presentation feature ascites/ jaundice/ bleed/ HE/ HRS . Only patient alcoholic cirrhosis cryptogenic cirrhosis ( etiology work negative ) enrol study . Sepsis ( Any culture positive : blood , urine , obvious source infection : UTI , LRTI ) Variceal bleed past 3 month Autoimmune disorder HCC ( Hepatocellular Carcinoma ) Multi organ failure Any feature decompensation form ascites/Jaundice/ HE ( grade 3 4 ) / HRS HIV seropositivity Essential hypertension Pregnancy Refusal participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>